Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Supportive and palliative care

1441O - Patient-reported outcomes in cancer patients newly diagnosed with brain metastases


21 Sep 2021


Proffered Paper session - Supportive and palliative care


Supportive and Palliative Care

Tumour Site


Guro Astrup


Annals of Oncology (2021) 32 (suppl_5): S1076-S1083. 10.1016/annonc/annonc679


G.L. Astrup1, S. Kaasa2, N.K. Aass1, M.J. Hjermstad1, T. Lundeby1, R. van Helvoirt3, J. Lund4, Ø. Paulsen5, O.E. Yri2

Author affiliations

  • 1 Department Of Oncology, Oslo University Hospital, 0424 - Oslo/NO
  • 2 Oncology Dept, Oslo University Hospital - The Norwegian Radium Hospital, 0424 - Oslo/NO
  • 3 Center For Cancer Treatment, Sørlandet Hospital, 4604 - Kristiansand/NO
  • 4 Department Of Oncology, Møre og Romsdal Hospital Trust, 6026 - Ålesund/NO
  • 5 Department Of Oncology, Telemark Hospital Trust, 3710 - Skien/NO


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1441O


Assessing patient-reported outcomes (PROs) is an important element of treatment and care of cancer patients with brain metastases (BMs). BMs are associated with substantial morbidity and mortality. Few prospective studies on PROs in patients with BMs exist. Further, poor accrual, differential dropout, missing data, timing of assessments, and response shift complicate interpretation of PROs in previous studies. We conducted a prospective, population-based study with clinical data and PROs to gain insight into the health-related quality of life (HRQOL) of patients with BMs.


Norwegian patients with newly verified BMs from solid cancers, who were adults (≥18 years) and provided written consent were included. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative (EORTC QLQ-C15-PAL) was used monthly to measure HRQOL. Student’s t-tests were used to examine differences in EORTC scores at baseline and 3 months.


725 patients have been included so far; mean age 66, 53% females, 45% with lung cancer, 79% with extracranial metastases, 59% with ECOG 0-1. 35% died within 3 months after BM diagnosis. The table shows HRQOL scores at baseline for the entire sample and baseline and 3 month scores for the 235 patients who completed both. Patients reported significantly lower physical functioning and more fatigue, pain, nausea/vomiting and dyspnea, and poorer appetite, but less sleep disturbances at 3 months compared to baseline. Table: 1441O

EORTC QLQ-C15-PAL scores of the patients (n=725)

EORTC QLQ-C15-PAL Baseline (n=725) Baseline (n=235) 3 months (n=235) p-value*
Mean (SD)
Global Quality of life 55.3 (25.5) 59.4 (25.2) 58.2 (22.9) 0.447
Physical functioning 68.6 (28.1) 76.5 (23.7) 72.1 (28.3) 0.019
Emotional functioning 76.2 (25.2) 77.9 (23.6) 80.6 (23.7) 0.089
Fatigue 42.6 (26.9) 37.3 (25.5) 41.4 (27.3) 0.039
Nausea/vomiting 14.3 (25.0) 10.6 (20.7) 14.4 (24.2) 0.027
Pain 26.6 (30.0) 20.9 (25.7) 25.4 (28.0) 0.010
Dyspnea 24.6 (29.1) 20.9 (27.0) 24.4 (27.6) 0.040
Sleep disturbances 34.3 (31.6) 34.2 (29.9) 25.5 (28.8) <0.001
Appetite loss 20.8 (30.9) 15.5 (25.8) 22.4 (29.4) 0.001
Constipation 25.6 (31.5) 20.7 (27.7) 23.2 (27.4) 0.215

Notes: * Comparison between baseline and 3 months (n=235). EORTC scores range from 0-100. Higher score represents a better functioning, or a higher level of symptoms.


Deterioration in most HRQOL scores was detected three months after inclusion in the study. Preliminary analyses indicate a healthy bias, in that those with poor HRQOL at baseline have died or are too frail to complete PRO measures.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.


The South-Eastern Norway Regional Health Authority.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.